Why $55 Million Flowed Into a Triple-Leveraged Biotech ETF Worth Less Than $600 Million

Traders poured tens of millions into a triple-leveraged biotech fund in a single day, a move that looks like bold conviction until you see what that same bet returned over five years.

24/7 Wall Street • Oct 20, 2026

Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism

Biotechnology stocks are showing signs of a renewed recovery, supported by a pickup in pharmaceutical mergers and acquisitions and investor interest in drug development pipelines. Key Takeaways: Big pharma acquisitions are hitting record highs to combat impending patent cliffs.

ETF Trends • Oct 12, 2026

Medical Technology Stocks: Innovation Endures As Valuations Reset

Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic. The starting point is to distinguish between medtech and other healthcare industries.

Seeking Alpha • May 2, 2026

LABU Could Rip Higher if Biotech Finally Gets Its Long-Awaited Breakout

If you bought XBI a year ago and held it, you are up roughly 65%. If you bought Direxion Daily S&P Biotech Bull 3X Shares (NYSEARCA:LABU) on the same day, you are up about 235%.

24/7 Wall Street • Apr 27, 2026

Equal-Weight ETFs Are the Play for Small-Cap Drug Development. Here's How to Position Now

Biotech has reasserted itself over the past year as drug approvals,

24/7 Wall Street • Apr 23, 2026

Global PMI: Tracking The Sectors Hit Hardest By The Middle East War

Survey data underscored how the war in the Middle East has already had a material impact on economic growth around the world. Drilling down deeper, the data showed weaker growth trends were recorded across all major industries globally.

Seeking Alpha • Apr 12, 2026

Triple-Leveraged Biotech ETF Doubles as Regulatory Winds Shift in 2026

Triple-leveraged ETFs aren't for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull 3X Shares (NASDAQ:LABU) offers the most aggressive way to capture that move.

24/7 Wall Street • Jan 16, 2026

Navigate Biotech's Crosscurrents With Direxion's LABU And LABD ETFs

Although the equities market often embodies chaos and capricious non-linearity, few sectors witness as much kinetic wildness like biotechnology. At its core, biotech represents an innovative push toward addressing the human condition — which is often found to be shockingly frail.

Benzinga • Dec 18, 2025

Top Performing Leveraged/Inverse ETFs: 11/16/2025

Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.

ETF Trends • Nov 19, 2025

New FDA Director Could Sway Biotech ETFs

Biotech stocks could sway toward the upside with the appointment of a new director at the Federal Drug Administration's Center for Drug Evaluation and Research. Dr. Richard Pazdur will take the reigns, bringing 26 years of related industry experience.

ETF Trends • Nov 14, 2025